Jiangsu Rec-Biotechnology
CompanyChina
Jiangsu Rec-Biotechnology develops 2 assets, the furthest in phase 3 (recombinant zoster vaccine in cardiovascular disease). Mostly vaccine acting on inflammation; based in China.
- 2
- Assets
- Furthest stage
- Phase 3
- 2
- Trials
- 1
- Signal
Pipeline
2Induces immunity against varicella-zoster virus using recombinant glycoprotein E with an adjuvant.
Phase 3, Vaccine, Inflammation, cardiovascular disease, herpes zoster
Recombinant subunit vaccine inducing immune response against varicella-zoster virus glycoprotein E.
Phase 1, Vaccine, herpes zoster
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Signals4
- Similar companies6